Our experiences span the entire lifecycle from discovery / development, licensing and product launch right through to government policy development.
Learn more about us
We serve a variety of clients ranging from global pharmaceutical, biopharmaceutical and life sciences companies to ministries of health in emerging markets.
The healthcare landscape is more complicated than ever. Product access and reimbursement is no longer a given and requires a deep understanding of payer dynamics. We help clients develop winning strategies to maximize access and pricing opportunity across all phases of development: from pre-clinical prioritization to final pricing assessment and value communication.
With global understanding of commercial and payer dynamics, we help clients develop tailored product as well as portfolio strategies that more accurately value future opportunity and position for success against an increasingly challenging market backdrop. Horizontal integration across the biopharma planning and launch process as well as a clear vision for the unmet need of tomorrow will be the keys to sustained commercial success.
Both innovation and government policy are rapidly evolving. There is growing demand internationally for better structured healthcare policies and systems that deliver against an increased standard of care while maintaining affordability and equity. We aim to ensure that policy development is informed by analysis, evidence, and expertise.
In this three-part series, CBPartners’ Digital Therapeutics & Health Technology Expertise Team interviews some of the leaders of the digital therapeutics (DTx) space to collect their thoughts on the current challenges and opportunities for DTx commercialization.
New cell therapy technologies show blockbuster potential for improved accessibility and efficacy in a wide range of indications, though these therapies come with their own downfalls that healthcare systems will need to adapt to in order for these products to reach their full potential.
An analysis of the key drug pricing proposals in the 2020 USA Election in terms of political focus, party priorities, implementation feasibility, and potential risk to biopharma.
Pharma and biotech companies should be prepared to make long-term investments in capability building, market development, and evidence generation to maximize the value of digital companions.
CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.
We place great value on the different backgrounds, identities, and expertise of the people we hire – because not only do diverse personalities contribute to a rich culture, diverse minds allow us to deliver the tailored, innovative solutions that our clients need.
CBPartners speaks regularly at international conferences around the globe, find out where we are next in our events calendar.
See all events